{"ticker": {"uuid": "d09d7c86-64b1-45ce-beb0-c7baa34da10f", "symbol": "YDES", "name": "YD Bio Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBITDA forward of YD Bio Limited \u2013 NASDAQ:YDES", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNaXNmUXlNcGdkMzJMZi1UTmthUVdCLWUtbDk0am1uNXV2LU5GbENyOGVsaWVVUFNGeFRDZHhGNlNhVHdCdHF2S0hfSzd1YkVrblBtT2lVOWFwZUF5QXFidXBWejVwOHlGRHR1WVV4ZmpQZjFOQ0pObjFNUmtXMlhNd1hjY25WdHlkdmJBY09EYmI5ZGVIdUN4QV9vUFh3ak1uUzM2akVZUWp1U3V3SVE?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T04:29:42+00:00", "published_display": "05 Jul 2026 04:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania By Investing.com", "summary": "YD Bio's affiliate, EG BioMed US Inc., has secured clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its operational reach to 46 U.S. states, Washington D.C., and Guam. The expansion comes as YD Bio's stock (NASDAQ:YDES) has seen a significant decline, trad", "url": "https://ca.investing.com/news/stock-market-news/yd-bio-affiliate-obtains-lab-licenses-in-rhode-island-pennsylvania-93CH-4718197", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:11:41", "published_display": "02 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YD Bio expands cancer-testing lab access to 46 states", "summary": "YD Bio (Nasdaq:YDES) announced that its affiliate, EG BioMed US, has secured out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited Bothell, Washington lab. This expansion grows its authorized operations to 46 U.S. states", "url": "https://www.stocktitan.net/news/YDES/yd-bio-expands-u-s-laboratory-footprint-to-46-states-strengthening-zond22vre7mz.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:40:23", "published_display": "02 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant and exercise for YD Bio (YDES) director Chang Kochi", "summary": "YD Bio Ltd director Chang Kochi reported exercising 5,749 Restricted Share Units (RSUs) into ordinary shares and simultaneously receiving a new grant of 5,749 RSUs on June 30, 2026. After these transactions, Kochi directly holds 7,830 ordinary shares. The new RSU grant has a targ", "url": "https://www.stocktitan.net/sec-filings/YDES/form-4-yd-bio-ltd-insider-trading-activity-8319e322b2aa.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:33:55", "published_display": "01 Jul 2026 19:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant and exercise update for YD Bio (YDES) director Lu", "summary": "YD Bio Ltd. director Lu Shao-Ta reported exercising 5,749 Restricted Share Units (RSUs) into ordinary shares and receiving a new grant of 5,749 RSUs. These transactions update his direct holdings to 7,830 ordinary shares and indirect holdings (through his spouse) to 51,151 ordina", "url": "https://www.stocktitan.net/sec-filings/YDES/form-4-yd-bio-ltd-insider-trading-activity-5adc209abb12.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:33:55", "published_display": "01 Jul 2026 19:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YD Bio Ltd (NASDAQ: YDES) Share Price, YDES Stock News, YDES Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE1EZDVuczZldGZJeDBoYjY1VjNJZzlOYWFrVEVCbmxuQlp5MFQ0TWZILTJxMzdBMDdhYUZ0ajlkWTNJU0pMT2Nqa001Y1dfbFZnb0VEbG53?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T16:47:56+00:00", "published_display": "01 Jul 2026 16:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YDES - YD Bio Ltd Stock Price and Quote", "summary": "This article provides detailed financial information and recent news for YD Bio Ltd (YDES). It includes stock performance, key financial metrics, insider and institutional ownership, and a list of significant corporate announcements such as financial results, strategic partnershi", "url": "https://finviz.com/stock?t=YDES", "source_name": "Finviz", "published_at": "2026-06-02T08:10:48", "published_display": "02 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] YD Bio Ltd SEC Filing", "summary": "This article reports on YD Bio Ltd.'s SEC Filing, specifically a Notice of Effectiveness for an EFFECT form submitted on May 29, 2026. The filing's impact and sentiment are noted as \"Neutral.\" The article also provides an overview of YD Bio's stock (NASDAQ: YDES), its market cap,", "url": "https://www.stocktitan.net/sec-filings/YDES/effect-yd-bio-ltd-sec-filing-9856a140001a.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:39:15", "published_display": "01 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Revenue climbs but YD Bio (Nasdaq: YDES) posts $8.3M 2025 net loss", "summary": "YD Bio (Nasdaq: YDES) reported a significant increase in net loss to $8.3 million in 2025, up from $1.4 million in 2024, despite a 17% rise in net revenue to $596,817. The widening loss was primarily driven by a surge in operating expenses, including higher professional fees, R&D", "url": "https://www.stocktitan.net/sec-filings/YDES/6-k-yd-bio-ltd-current-report-foreign-issuer-e963a1736f35.html", "source_name": "Stock Titan", "published_at": "2026-05-03T21:40:08", "published_display": "03 May 2026 21:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a $13.9M equity raise, YD Bio enters 2026 with $6M cash", "summary": "YD Bio (Nasdaq: YDES) reported full-year 2025 results with net revenue increasing by 17% to $596.8K, while net loss widened significantly to $8.31M from $1.41M in 2024, primarily due to increased operating expenses including R&D and staff costs. Despite the wider loss, the compan", "url": "https://www.stocktitan.net/news/YDES/yd-bio-limited-reports-full-year-2025-financial-0vtk0optpz7o.html", "source_name": "Stock Titan", "published_at": "2026-05-01T07:09:42", "published_display": "01 May 2026 07:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "YDES Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for YD Bio Ltd (YDES). As of April 2, 2026, the overall technical consensus for YDES is a \"Sell,\" with a combination of moving averages and oscillators pointing to this sentiment. Key indicators like MACD and cer", "url": "https://intellectia.ai/en/stock/YDES/technical", "source_name": "Intellectia AI", "published_at": "2026-04-02T07:10:58", "published_display": "02 Apr 2026 07:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "YDES Stock Price and Chart \u2014 NASDAQ:YDES", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE8wdXJ0ZFN0SURILVFiQXYtUE9qOFE1ZDk2V2NIbzM3OHRXSnNaT3RoSDRLZ1hzemZDTy1NUEZiMVdBM0FMMi1vUFF3ajExUkxRWVpaTnZzSlZmSXVM?oc=5", "source_name": "TradingView", "published_at": "2025-08-29T14:41:40+00:00", "published_display": "29 Aug 2025 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBITDA forward of YD Bio Limited \u2013 NASDAQ:YDES", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNaXNmUXlNcGdkMzJMZi1UTmthUVdCLWUtbDk0am1uNXV2LU5GbENyOGVsaWVVUFNGeFRDZHhGNlNhVHdCdHF2S0hfSzd1YkVrblBtT2lVOWFwZUF5QXFidXBWejVwOHlGRHR1WVV4ZmpQZjFOQ0pObjFNUmtXMlhNd1hjY25WdHlkdmJBY09EYmI5ZGVIdUN4QV9vUFh3ak1uUzM2akVZUWp1U3V3SVE?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T04:29:42+00:00", "published_display": "05 Jul 2026 04:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania By Investing.com", "summary": "YD Bio's affiliate, EG BioMed US Inc., has secured clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its operational reach to 46 U.S. states, Washington D.C., and Guam. The expansion comes as YD Bio's stock (NASDAQ:YDES) has seen a significant decline, trad", "url": "https://ca.investing.com/news/stock-market-news/yd-bio-affiliate-obtains-lab-licenses-in-rhode-island-pennsylvania-93CH-4718197", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:11:41", "published_display": "02 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YD Bio expands cancer-testing lab access to 46 states", "summary": "YD Bio (Nasdaq:YDES) announced that its affiliate, EG BioMed US, has secured out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited Bothell, Washington lab. This expansion grows its authorized operations to 46 U.S. states", "url": "https://www.stocktitan.net/news/YDES/yd-bio-expands-u-s-laboratory-footprint-to-46-states-strengthening-zond22vre7mz.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:40:23", "published_display": "02 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant and exercise for YD Bio (YDES) director Chang Kochi", "summary": "YD Bio Ltd director Chang Kochi reported exercising 5,749 Restricted Share Units (RSUs) into ordinary shares and simultaneously receiving a new grant of 5,749 RSUs on June 30, 2026. After these transactions, Kochi directly holds 7,830 ordinary shares. The new RSU grant has a targ", "url": "https://www.stocktitan.net/sec-filings/YDES/form-4-yd-bio-ltd-insider-trading-activity-8319e322b2aa.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:33:55", "published_display": "01 Jul 2026 19:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant and exercise update for YD Bio (YDES) director Lu", "summary": "YD Bio Ltd. director Lu Shao-Ta reported exercising 5,749 Restricted Share Units (RSUs) into ordinary shares and receiving a new grant of 5,749 RSUs. These transactions update his direct holdings to 7,830 ordinary shares and indirect holdings (through his spouse) to 51,151 ordina", "url": "https://www.stocktitan.net/sec-filings/YDES/form-4-yd-bio-ltd-insider-trading-activity-5adc209abb12.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:33:55", "published_display": "01 Jul 2026 19:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YD Bio Ltd (NASDAQ: YDES) Share Price, YDES Stock News, YDES Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE1EZDVuczZldGZJeDBoYjY1VjNJZzlOYWFrVEVCbmxuQlp5MFQ0TWZILTJxMzdBMDdhYUZ0ajlkWTNJU0pMT2Nqa001Y1dfbFZnb0VEbG53?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T16:47:56+00:00", "published_display": "01 Jul 2026 16:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YDES - YD Bio Ltd Stock Price and Quote", "summary": "This article provides detailed financial information and recent news for YD Bio Ltd (YDES). It includes stock performance, key financial metrics, insider and institutional ownership, and a list of significant corporate announcements such as financial results, strategic partnershi", "url": "https://finviz.com/stock?t=YDES", "source_name": "Finviz", "published_at": "2026-06-02T08:10:48", "published_display": "02 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] YD Bio Ltd SEC Filing", "summary": "This article reports on YD Bio Ltd.'s SEC Filing, specifically a Notice of Effectiveness for an EFFECT form submitted on May 29, 2026. The filing's impact and sentiment are noted as \"Neutral.\" The article also provides an overview of YD Bio's stock (NASDAQ: YDES), its market cap,", "url": "https://www.stocktitan.net/sec-filings/YDES/effect-yd-bio-ltd-sec-filing-9856a140001a.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:39:15", "published_display": "01 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revenue climbs but YD Bio (Nasdaq: YDES) posts $8.3M 2025 net loss", "summary": "YD Bio (Nasdaq: YDES) reported a significant increase in net loss to $8.3 million in 2025, up from $1.4 million in 2024, despite a 17% rise in net revenue to $596,817. The widening loss was primarily driven by a surge in operating expenses, including higher professional fees, R&D", "url": "https://www.stocktitan.net/sec-filings/YDES/6-k-yd-bio-ltd-current-report-foreign-issuer-e963a1736f35.html", "source_name": "Stock Titan", "published_at": "2026-05-03T21:40:08", "published_display": "03 May 2026 21:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a $13.9M equity raise, YD Bio enters 2026 with $6M cash", "summary": "YD Bio (Nasdaq: YDES) reported full-year 2025 results with net revenue increasing by 17% to $596.8K, while net loss widened significantly to $8.31M from $1.41M in 2024, primarily due to increased operating expenses including R&D and staff costs. Despite the wider loss, the compan", "url": "https://www.stocktitan.net/news/YDES/yd-bio-limited-reports-full-year-2025-financial-0vtk0optpz7o.html", "source_name": "Stock Titan", "published_at": "2026-05-01T07:09:42", "published_display": "01 May 2026 07:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YDES Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for YD Bio Ltd (YDES). As of April 2, 2026, the overall technical consensus for YDES is a \"Sell,\" with a combination of moving averages and oscillators pointing to this sentiment. Key indicators like MACD and cer", "url": "https://intellectia.ai/en/stock/YDES/technical", "source_name": "Intellectia AI", "published_at": "2026-04-02T07:10:58", "published_display": "02 Apr 2026 07:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YDES Stock Price and Chart \u2014 NASDAQ:YDES", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE8wdXJ0ZFN0SURILVFiQXYtUE9qOFE1ZDk2V2NIbzM3OHRXSnNaT3RoSDRLZ1hzemZDTy1NUEZiMVdBM0FMMi1vUFF3ajExUkxRWVpaTnZzSlZmSXVM?oc=5", "source_name": "TradingView", "published_at": "2025-08-29T14:41:40+00:00", "published_display": "29 Aug 2025 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 81, "total_relevant": 21, "sentiment_summary": {"positive": 1, "negative": 4, "neutral": 16, "score": 47, "total": 21, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 78, "events": [{"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "general", "label": "Market update", "weight": 4.4, "count": 8}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.23, "latest_week": "2026-07-10", "one_week_move": 17.4, "four_week_move": -31.8, "twelve_week_move": -59.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.059396, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -77.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 28.4065, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+17.4% over one week, -31.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 6}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "Investing.com Canada", "count": 1}, {"label": "Kalkine", "count": 1}, {"label": "Finviz", "count": 1}, {"label": "Intellectia AI", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 12}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 12}, {"label": "Market update", "count": 8}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "12", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+17.4% over one week, -31.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBITDA forward of YD Bio Limited \u2013 NASDAQ:YDES"}], "updated_at": "2026-07-18T02:10:25.392036+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}